I would also be looking into the market / revenue potential for BOTs product pipeline, combined with a lack of competing new products in the skin disease space over the past decade or so. I'd say that has a lot to do with the higher valuation. That and their BOD is absolutely water tight
Ann: Dronabinol Supply Agreement/Sleep Apnoea Trial Update, page-30
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)